$ITCI
Intra-Cellular Therapies, Inc.

2015 Q2 Form 10-Q Financial Statement

#000119312515162498 Filed on April 30, 2015

View on sec.gov

Income Statement

Concept 2015 Q2 2015 Q1 2014 Q1
Revenue $57.39K $3.315K $167.8K
YoY Change -73.82% -98.02% -71.95%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.990M $3.770M $1.910M
YoY Change 88.21% 97.38% 81.9%
% of Gross Profit
Research & Development $17.76M $18.63M $2.829M
YoY Change 555.52% 558.55% -42.87%
% of Gross Profit
Depreciation & Amortization $30.00K $15.24K $6.317K
YoY Change 366.56% 141.25% 1.9%
% of Gross Profit
Operating Expenses $21.75M $22.40M $2.829M
YoY Change 702.61% 691.86% -42.87%
Operating Profit -$21.69M -$22.40M -$4.574M
YoY Change 370.36% 389.69% -15.3%
Interest Expense $180.0K $110.0K $5.041K
YoY Change 8758.27% 2082.11% -97.91%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$21.51M -$22.29M -$4.540M
YoY Change 374.83% 390.97% -19.5%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$21.51M -$22.29M -$4.543M
YoY Change 374.49% 390.54% -19.42%
Net Earnings / Revenue -37482.69% -672302.38% -2707.77%
Basic Earnings Per Share
Diluted Earnings Per Share -$614.6K -$724.2K -$171.5K
COMMON SHARES
Basic Shares Outstanding 34.97M shares 34.93M shares 29.22M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2015 Q2 2015 Q1 2014 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $204.0M $235.2M $145.6M
YoY Change 45.2% 61.54%
Cash & Equivalents $71.42M $100.8M $143.6M
Short-Term Investments $132.6M $134.4M $2.000M
Other Short-Term Assets $8.600M $1.300M $600.0K
YoY Change 1620.0% 116.67%
Inventory
Prepaid Expenses
Receivables $9.118K $3.315K $167.8K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $212.6M $236.5M $146.4M
YoY Change 50.57% 61.57%
LONG-TERM ASSETS
Property, Plant & Equipment $722.1K $559.7K $65.08K
YoY Change 1030.98% 760.1%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $70.94K $70.94K $200.4K
YoY Change 0.0% -64.61%
Total Long-Term Assets $793.1K $630.7K $265.5K
YoY Change 488.36% 137.51%
TOTAL ASSETS
Total Short-Term Assets $212.6M $236.5M $146.4M
Total Long-Term Assets $793.1K $630.7K $265.5K
Total Assets $213.4M $237.1M $146.6M
YoY Change 50.98% 61.71%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.911M $4.574M $2.143M
YoY Change 1081.14% 113.48%
Accrued Expenses $4.400M $10.00M $1.800M
YoY Change 91.3% 455.56%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $9.318M $14.59M $3.912M
YoY Change 240.17% 273.06%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $500.0K $200.0K
YoY Change
Total Long-Term Liabilities $500.0K $160.1K $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $9.318M $14.59M $3.912M
Total Long-Term Liabilities $500.0K $160.1K $0.00
Total Liabilities $9.839M $14.75M $3.900M
YoY Change 264.4% 278.28%
SHAREHOLDERS EQUITY
Retained Earnings -$132.1M -$110.5M -$62.11M
YoY Change 98.16% 77.99%
Common Stock $335.7M $333.0M $2.922K
YoY Change 11440666.36% 11394548.77%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $203.6M $222.4M $142.7M
YoY Change
Total Liabilities & Shareholders Equity $213.4M $237.1M $146.6M
YoY Change 50.98% 61.71%

Cashflow Statement

Concept 2015 Q2 2015 Q1 2014 Q1
OPERATING ACTIVITIES
Net Income -$21.51M -$22.29M -$4.543M
YoY Change 374.49% 390.54% -19.42%
Depreciation, Depletion And Amortization $30.00K $15.24K $6.317K
YoY Change 366.56% 141.25% 1.9%
Cash From Operating Activities -$31.00M -$15.71M -$6.980M
YoY Change 496.15% 125.07%
INVESTING ACTIVITIES
Capital Expenditures -$190.0K $520.4K $3.120K
YoY Change 1800.0% 16579.36% -38.28%
Acquisitions
YoY Change
Other Investing Activities $1.640M -$66.18M $0.00
YoY Change -103.46%
Cash From Investing Activities $1.440M -$66.70M $0.00
YoY Change -103.03%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $129.9M $116.2M
YoY Change 11.8%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 170.0K 121.9M 115.5M
YoY Change 0.0% 5.58%
NET CHANGE
Cash From Operating Activities -31.00M -15.71M -6.980M
Cash From Investing Activities 1.440M -66.70M 0.000
Cash From Financing Activities 170.0K 121.9M 115.5M
Net Change In Cash -29.39M 39.48M 108.5M
YoY Change -44.0% -63.6%
FREE CASH FLOW
Cash From Operating Activities -$31.00M -$15.71M -$6.980M
Capital Expenditures -$190.0K $520.4K $3.120K
Free Cash Flow -$30.81M -$16.23M -$6.983M
YoY Change 493.64% 132.42%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2014Q1 us-gaap Share Price
SharePrice
17.50
CY2015Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
34967837 shares
CY2014Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
143618247
CY2015Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
34967837 shares
CY2015Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
34967837 shares
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
2860549 shares
CY2015Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
11.34
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1323832 shares
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
5.75
CY2015Q1 us-gaap Business Acquisition Percentage Of Voting Interests Acquired
BusinessAcquisitionPercentageOfVotingInterestsAcquired
1.00 pure
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
11.34
CY2015Q1 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
20100000 shares
CY2015Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2860549 shares
CY2015Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2233281
CY2015Q1 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
9029493
CY2015Q1 us-gaap Liabilities Current
LiabilitiesCurrent
14592741
CY2015Q1 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
160112
CY2015Q1 us-gaap Common Stock Value
CommonStockValue
3497
CY2015Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-33904
CY2015Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
4574351
CY2015Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-110542781
CY2015Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
332948140
CY2015Q1 us-gaap Stockholders Equity
StockholdersEquity
222374952
CY2015Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
237127805
CY2015Q1 us-gaap Liabilities
Liabilities
14752853
CY2015Q1 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
12000
CY2015Q1 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
988897
CY2015Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
100802133
CY2015Q1 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
22600000
CY2015Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
559709
CY2015Q1 us-gaap Assets Fair Value Disclosure Recurring
AssetsFairValueDisclosureRecurring
189502000
CY2015Q1 us-gaap Available For Sale Securities
AvailableForSaleSecurities
134424335
CY2015Q1 us-gaap Available For Sale Securities Noncurrent
AvailableForSaleSecuritiesNoncurrent
36500000
CY2015Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1267369
CY2015Q1 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
46000
CY2015Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2792990
CY2015Q1 us-gaap Assets
Assets
237127805
CY2015Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
3315
CY2015Q1 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
134458000
CY2015Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
70944
CY2015Q1 us-gaap Assets Current
AssetsCurrent
236497152
CY2015Q1 itci Area Of Office Space Leased
AreaOfOfficeSpaceLeased
16753 sqft
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
35150924
CY2014Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
29499059 shares
CY2014Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
29499059 shares
CY2014Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
9.20
CY2014Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2233460 shares
CY2014Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2228413
CY2014Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
7529241
CY2014Q4 us-gaap Liabilities Current
LiabilitiesCurrent
10557064
CY2014Q4 us-gaap Common Stock Value
CommonStockValue
2950
CY2014Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-104633
CY2014Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2052765
CY2014Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-88255957
CY2014Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
208912345
CY2014Q4 us-gaap Stockholders Equity
StockholdersEquity
120554705
CY2014Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
131111769
CY2014Q4 us-gaap Liabilities
Liabilities
10557064
CY2014Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
1000
CY2014Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
975058
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
61325044
CY2014Q4 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
8500000
CY2014Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
54553
CY2014Q4 us-gaap Assets Fair Value Disclosure Recurring
AssetsFairValueDisclosureRecurring
115815000
CY2014Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
68320672
CY2014Q4 us-gaap Available For Sale Securities Noncurrent
AvailableForSaleSecuritiesNoncurrent
31800000
CY2014Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1288953
CY2014Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
106000
CY2014Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2282966
CY2014Q4 us-gaap Assets
Assets
131111769
CY2014Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
51603
CY2014Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
68425000
CY2014Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
70944
CY2014Q4 us-gaap Assets Current
AssetsCurrent
130986272
CY2014Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
7063300 shares
CY2014Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
115400000
CY2014Q1 itci Share Issued During Period Shares Underwriters New Issues
ShareIssuedDuringPeriodSharesUnderwritersNewIssues
921300 shares
CY2015Q1 itci Net Proceeds From Initial Public Offering
NetProceedsFromInitialPublicOffering
121800000
CY2015Q1 itci Share Issued During Period Shares Underwriters New Issues
ShareIssuedDuringPeriodSharesUnderwritersNewIssues
661481 shares
CY2014Q3 itci Registration Statement Filing Date
RegistrationStatementFilingDate
2014-08-29
CY2014Q3 itci Entity Securities Universal Shelf Registration
EntitySecuritiesUniversalShelfRegistration
150000000
CY2014Q3 itci Period After Filing Shelf Registration Statement Expires
PeriodAfterFilingShelfRegistrationStatementExpires
P3Y
CY2014 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y3M18D
CY2014 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2014Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-6982837
CY2014Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
26475907 shares
CY2014Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.17
CY2014Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
738005
CY2014Q1 us-gaap Excess Tax Benefit From Share Based Compensation Operating Activities
ExcessTaxBenefitFromShareBasedCompensationOperatingActivities
0
CY2014Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-108247
CY2014Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-4574463
CY2014Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-4543284
CY2014Q1 us-gaap Income Taxes Paid
IncomeTaxesPaid
3900
CY2014Q1 us-gaap Revenues
Revenues
167787
CY2014Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3120
CY2014Q1 us-gaap Net Income Loss
NetIncomeLoss
-4543284
CY2014Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
36220
CY2014Q1 us-gaap Interest Paid
InterestPaid
5041
CY2014Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-168531
CY2014Q1 us-gaap Interest Expense
InterestExpense
5041
CY2014Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2829299
CY2014Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
108467323
CY2014Q1 us-gaap Depreciation
Depreciation
6317
CY2014Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
115453280
CY2014Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
116191285
CY2014Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1670114
CY2014Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-3120
CY2014Q1 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
4742250
CY2014Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1912951
CY2014Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1252288
CY2014Q1 us-gaap Share Based Compensation
ShareBasedCompensation
199754
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
682473 shares
CY2015Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.82
CY2015Q1 dei Document Type
DocumentType
10-Q
CY2015Q1 dei Entity Registrant Name
EntityRegistrantName
Intra-Cellular Therapies, Inc.
CY2015Q1 dei Trading Symbol
TradingSymbol
ITCI
CY2015Q1 dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2015Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-15709090
CY2015Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
P10Y
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00 pure
CY2015Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y6M
CY2015Q1 us-gaap Lessee Leasing Arrangements Operating Leases Term Of Contract
LesseeLeasingArrangementsOperatingLeasesTermOfContract
P11Y
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.016 pure
CY2015Q1 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> <b>Use of Estimates</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Although actual results could differ from those estimates, management does not believe that such differences would be material.</p> </div>
CY2015Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
30775287 shares
CY2015Q1 dei Document Period End Date
DocumentPeriodEndDate
2015-03-31
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
0
CY2015Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y9M18D
CY2015Q1 dei Amendment Flag
AmendmentFlag
false
CY2015Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2015Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2015
CY2015Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
0 shares
CY2015Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
17.57
CY2015Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001567514
CY2015Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.72
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.80 pure
CY2015Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2015Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b>Concentration of Credit Risk</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> Cash equivalents are held with major financial institutions in the United States. Certificates of deposit held with banks may exceed the amount of insurance provided on such deposits. Generally, these deposits may be redeemed upon demand and, therefore, bear minimal risk.</p> </div>
CY2015Q1 us-gaap Income Taxes Paid
IncomeTaxesPaid
1600
CY2015Q1 us-gaap Revenues
Revenues
3315
CY2015Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
520396
CY2015Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
55384 shares
CY2015Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
293214
CY2015Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-151325
CY2015Q1 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
71142903
CY2015Q1 us-gaap Excess Tax Benefit From Share Based Compensation Operating Activities
ExcessTaxBenefitFromShareBasedCompensationOperatingActivities
0
CY2015Q1 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
70729
CY2015Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-21584
CY2015Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-22400740
CY2015Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-21216095
CY2015Q1 us-gaap Net Income Loss
NetIncomeLoss
-22286824
CY2015Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
113916
CY2015Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-48288
CY2015Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
18632427
CY2015Q1 us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
160112
CY2015Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
39477089
CY2015Q1 us-gaap Depreciation
Depreciation
15240
CY2015Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
121890834
CY2015Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
122083012
CY2015Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1514091
CY2015Q1 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
45682
CY2015Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-66704655
CY2015Q1 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
22404055
CY2015Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
101036
CY2015Q1 us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
4958644
CY2015Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3771628
CY2015Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2521586
CY2015Q1 us-gaap Share Based Compensation
ShareBasedCompensation
2099826
CY2015Q1 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2015Q1 itci Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageRemainingContractualTerm
P3Y9M18D
CY2015Q1 itci Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Remaining Contractual Term2
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm2
P9Y9M18D
CY2015Q1 itci Available For Sale Securities Maturity Period
AvailableForSaleSecuritiesMaturityPeriod
More than three months
CY2015Q1 itci Maturity Period Of Liquid Investments To Be Considered As Cash Equivalents
MaturityPeriodOfLiquidInvestmentsToBeConsideredAsCashEquivalents
Three months or less

Files In Submission

Name View Source Status
0001193125-15-162498-index-headers.html Edgar Link pending
0001193125-15-162498-index.html Edgar Link pending
0001193125-15-162498.txt Edgar Link pending
0001193125-15-162498-xbrl.zip Edgar Link pending
d914329d10q.htm Edgar Link pending
d914329dex311.htm Edgar Link pending
d914329dex312.htm Edgar Link pending
d914329dex32.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
itci-20150331.xml Edgar Link completed
itci-20150331.xsd Edgar Link pending
itci-20150331_cal.xml Edgar Link unprocessable
itci-20150331_def.xml Edgar Link unprocessable
itci-20150331_lab.xml Edgar Link unprocessable
itci-20150331_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending